CN110982791A - Preparation and screening method of hybridoma cells secreting AXL antibody - Google Patents
Preparation and screening method of hybridoma cells secreting AXL antibody Download PDFInfo
- Publication number
- CN110982791A CN110982791A CN201911371276.XA CN201911371276A CN110982791A CN 110982791 A CN110982791 A CN 110982791A CN 201911371276 A CN201911371276 A CN 201911371276A CN 110982791 A CN110982791 A CN 110982791A
- Authority
- CN
- China
- Prior art keywords
- axl
- cells
- hybridoma
- antibody
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 39
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 29
- 238000012216 screening Methods 0.000 title claims abstract description 26
- 230000003248 secreting effect Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 36
- 230000003053 immunization Effects 0.000 claims abstract description 17
- 238000002649 immunization Methods 0.000 claims abstract description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 12
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract description 12
- 210000004989 spleen cell Anatomy 0.000 claims abstract description 12
- 238000005406 washing Methods 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 210000000952 spleen Anatomy 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 210000004988 splenocyte Anatomy 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 25
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101150022345 GAS6 gene Proteins 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000037432 Thymic tumor Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 230000005944 tissue migration Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- FEPMHVLSLDOMQC-UHFFFAOYSA-N virginiamycin-S1 Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC=CC=2)N(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O FEPMHVLSLDOMQC-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The application provides a preparation and screening method of hybridoma cells secreting AXL antibody, belonging to the field of biology and antibody engineering. The method for preparing and screening hybridoma cells secreting AXL antibody according to the present application can produce spleen cells capable of producing high titer after primary immunization and several booster immunizations, and can produce hybridoma cells capable of continuously producing high titer and continuously dividing and proliferating by fusing spleen cells and myeloma cells.
Description
Technical Field
The application relates to the fields of biology and antibody engineering, in particular to a preparation and screening method of hybridoma cells secreting AXL antibody.
Background
AXL belongs to Tyro-3 family receptor tyrosine kinase, also called Ark, UFO or Tyro-7, the ligand is Gas6, Gas6 is a protein with the molecular weight of 70kDa, and is homologous with anticoagulant factor S, after the AXL is combined with the ligand and activated, a series of signal cascades are caused, and PI3K-Akt and Ras/Erk and β -catenin/TCF pathways are activated.
AXL is highly expressed abnormally in various tumor tissues, such as breast cancer, colon cancer, prostate cancer, gastric cancer, endometrial cancer, renal cancer, hepatocellular carcinoma, thymic tumor, esophageal sarcoma, chronic myelolymphoma, acute myelogenous lymphoma, melanoma, and head and neck tumors.
AXL has been shown to be abnormally high-surface in highly aggressive breast cancers and highly correlated with tumor migration. In vitro experiments have shown that tumor tissue migration and invasion is dependent on AXL activity, which is inhibited by treatment with antibodies (WO 04008147). Similarly, inhibition of AXL in vivo, such as expression of an inactive AXL or inhibition of AXL expression using siRNA, effectively blocks the growth of transplanted tumors in mice.
To date, several AXL antibodies have been developed for clinical treatment, such as US20190352407a1, and some AXL antibodies have been prepared as drug-conjugated antibodies, such as chinese patent CN110536703A, for direct killing of tumor tissues. AXL is considered to be a high-grade tumor tissue in various tumor tissues, and as a main driver in the process of generation and development of tumors, the drug development potential of AXL is not completely released. The main reasons are as follows: first, the blocking function of the existing antibodies is not high; secondly, the strategy of killing the tumor by relying on the European Union drug may limit the application range of the tumor due to potential toxicity. Based on the inference, the antibody with high blocking activity is obtained by screening, and therapeutic means except the ADC strategy is explored through a genetic engineering means, so that the potential druggy advantage is achieved, and an alternative solution is provided for the unmet clinical requirement.
Disclosure of Invention
The application discloses a method for preparing and screening hybridoma cells secreting AXL antibody, which comprises the following steps:
injecting 50 mu g of AXL immunogen mixture into an immunized mouse, detecting the antibody titer, stopping immunization when the antibody titer reaches 106;
taking a spleen of a mouse, and preparing splenocyte fluid; adding a PEG solution into the spleen cell fluid and the myeloma cell fluid under the condition of water bath at 40 ℃ for fusion, and centrifuging to obtain a hybridoma cell mixture;
resuspending the hybridoma cell mixture;
coating an AXL antigen, adding a hybridoma cell mixture, incubating for 1h, washing and patting dry, adding a secondary antibody, incubating and patting dry, and terminating reaction and screening to obtain a positive hybridoma cell secreting an AXL antibody; and the affinity of the hybridoma cells was detected by ELISA.
In some of the foregoing embodiments, the AXL immunogen mixture is obtained by mixing AXL-mFc fusion protein and freund's complete adjuvant in a mass ratio of 1: 1;
the method also comprises 3 times of boosting immunity before the detection of the antibody titer; the immunogen for strengthening immunity is obtained by mixing AXL-mFc fusion protein and Freund's incomplete adjuvant according to the mass ratio of 1: 1; the booster immunization was performed once every two weeks.
In the embodiment, after the immunogen and Freund's complete adjuvant are used for immunizing the mouse, the boosting immunization is carried out for multiple times, so that the binding effect of the antibody can be improved, and the affinity of the generated antibody and the antigen can be improved.
In some of the foregoing embodiments, the myeloma cells are SP20 cells, and the concentration of SP20 cells is 1 × 107one/mL.
In some of the foregoing embodiments, the ratio of spleen cells to myeloma cells is 3: 1.
In the examples, it is advantageous that the spleen cells are fully homozygously fused with myeloma cells by mixing an excess of spleen cells with myeloma cells.
In some of the foregoing embodiments, the PEG solution is preheated to 40 ℃.
In the examples, preheating the PEG solution to 40 deg.C also facilitates cell fusion, and since the heating temperature becomes high, the fluidity of cell membrane is enhanced, and the fusion of spleen cells and myeloma cells can be accelerated.
In some of the foregoing embodiments, resuspending the hybridoma cell mixture comprises diluting the cells to 5 × 10 with 20% FBS medium4Concentration per well, 5% CO at 37 ℃2Culturing for 7-10 days under the condition.
In some of the foregoing embodiments, the amount of coated AXL antigen is 2 μ g/well.
In some of the foregoing embodiments, the conditions for screening for positive secreted AXL antibodies are OD450The value is greater than 1.
In some of the foregoing embodiments, the antigen to detect the affinity of the hybridoma cells is Gas 6-His.
In some of the foregoing embodiments, 0.5. mu.g/mL AXL-mFc is mixed with the hybridoma cells at a ratio of 1:1 as the primary antibody.
Compared with the prior art, the beneficial effect of this application is: the method for preparing and screening hybridoma cells secreting AXL antibody according to the present application can produce spleen cells capable of producing high titer after primary immunization and several booster immunizations, and can produce hybridoma cells capable of continuously producing high titer and continuously dividing and proliferating by fusing spleen cells and myeloma cells.
Drawings
FIG. 1 is a graph of an antibody binding experiment of Experimental example 3;
FIG. 2 is a graph showing the results of an antibody blocking test in Experimental example 4;
FIG. 3 is a graph showing the results of the flow cytometric screening experiment in Experimental example 5.
Detailed Description
Embodiments of the present application will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present application and should not be construed as limiting the scope of the present application. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The features and properties of the present application are described in further detail below with reference to examples.
Example 1
This example provides a method for preparing and screening hybridoma cells that secrete AXL antibody, comprising the steps of:
the selected mice are BALA/C, healthy female mice of 6-8 weeks of age. The specific immunization operation steps are as follows:
1.1 Freund's complete adjuvant is adopted for the first immunization, the ratio of AXL-mFc immune antigen (fusion protein) to the immune adjuvant (Freund's complete adjuvant) is 1:1, the antigen and the adjuvant are only required to be mixed softly before the immunization (note: the antigen and the adjuvant are placed on ice before the immunization), the abdominal subcutaneous multi-point injection mode is adopted, and 50 mu g of each point is injected;
1.2 consecutive 3 boosts two weeks apart: injection of 30. mu.g per spot with Freund's incomplete adjuvant;
1.3, detecting the antibody titer, diluting the antigen AXL-hFc with a coating solution, and coating 1 mu g of antigen in each hole;
1.4 adding 50 mu L/hole into the plate hole of the enzyme label, and placing the plate hole at 4 ℃ overnight or 37 ℃ for coating for 2 hours; discarding the liquid in the hole, washing with 200 μ L of washing solution for 3 times, and drying; adding 200 μ L of blocking solution per well, and blocking at 4 deg.C overnight or 37 deg.C for 2 hr
1.5 washing solution 200. mu.L for 3 times; at this time, the coating plate can be stored at-20 ℃ or 4 ℃ for later use; adding 50 μ L primary antibody (mouse serum to be detected) into each well, and simultaneously setting positive and negative control wells; incubating at 37 ℃ for 1 h; washing with 200 μ L of washing solution for 5 times, and drying;
1.6 adding enzyme-labeled secondary antibody, incubating at 37 ℃ for 1h with 50 mu L of each well, washing with 200 mu L of washing solution for 5 times, and patting dry; adding 50 mu L of substrate solution TMB, and developing for 2-15min at 37 ℃; at 2mol/L H2SO4Stopping the reaction, and reading an OD value by an enzyme-labeling instrument at 450 nm; as a result, cell fusion was carried out so that the antibody titer reached more than the power of 6 of 10.
1.7 the puncture immunization is carried out at two weeks intervals, at the moment, the adjuvant is not added, only the antigen is used for carrying out the abdominal cavity immunization, each point is injected with 50 mu g, and the cell fusion can be carried out after 3 days of the puncture immunization
Example 2
In this example, spleen cells and myeloma cells were fused, and the specific procedures were as follows:
1.1 removing one side of eyeball to bleed, matching with vertebra dislocation, and putting the killed mouse in 70% alcohol; the skin inside the left hind thigh groove of the mouse was lifted with forceps, and the ligature was exposed by lateral and vertical scissors or by hand tearing. For lymph nodes in the groin, they were removed and immersed in 10ml of MPI 1640 medium (in a 9cm dish). Carefully taking off the spleen, immersing in the culture medium, carefully cutting off excessive white fat or connective tissue, clamping and immersing in fresh culture medium, and shaking to wash the spleen for 1-2 minutes;
1.2 the washed spleen and lymph nodes were transferred into a cell sieve, which was previously immersed in 20mL fresh medium; grinding spleen in cell sieve with syringe push head, transferring culture medium (containing cells) to clean centrifuge tube; slowly adding 20mL of culture medium into the cell sieve for washing; transferring the filtered cells into a centrifuge tube, gently blowing and beating liquid in the centrifuge tube, and centrifuging; 1000rpm, 5min, abandoning the supernatant; adding 40mL of culture medium, re-suspending the cells, centrifuging again, and discarding the supernatant;
1.3 add 1-5mL erythrocyte lysate (Sigma, R7757-100ML) into the tube, resuspend, carefully blow for 1-2 min; adding 40mL of culture medium to stop the cracking reaction; centrifuging: 1000rpm, 5min, abandoning the supernatant; the cells were resuspended by adding 10mL of medium;
1.4 Take 10. mu.L of cell suspension to transfer to a clean EP tube and add 90. mu.L of medium to dilute, take 10. mu.L of this dilution to a new EP tube and add 10. mu.L of 4% tryptan blue. Counting the cells under an inverted microscope and calculating the cell viability;
1.5 the majority of the remaining cells were brought to 30mL volume in culture medium, centrifuged, and the supernatant discarded (at this point water bath 40C was set up and PEG solution (Sigma 1450) was preheated);
1.6 resuspend splenocytes in 10mL of medium, as 1:3 was added SP20 (previously harvested, washed, resuspended in media,. about.10 ^ 7/mL). Wherein SP 20: splenocytes as 1: 3(SP20, preferably 10-20%);
1.7 the volume is adjusted to 20mL with medium and centrifuged. Discarding the supernatant; injecting 40C water into the beaker, and placing the tube filled with the cells in the beaker in water bath for about 2 min; slowly dripping 1mL of preheated PEG into the tube within 60s, adding and uniformly mixing, and keeping in a water bath;
1.8 sucking the cell suspension, slowly dripping the cell suspension back into the tube, and keeping a water bath; slowly adding 1mL of culture medium within 60s, uniformly mixing while adding, and keeping in a water bath; slowly adding 10mL of culture medium, and continuously mixing and bathing; slowly adding a culture medium, and fixing the volume to 20 mL; mixing, and water bathing for 10 min. (the water temperature is slowly reduced to the room temperature), centrifuging and discarding the supernatant; obtaining a hybridoma cell mixture.
1.8 at 5X 10 per well4Per cell, 100. mu.L culture solution calculation required 96-well plate(Corning COSTAR 3599) and medium (complete medium, P/S, 20% FBS, HAT), suspending the cells at full medium weight and dispensing into culture plates; culturing at 37 deg.C with 5% CO2 for 7-10 days; taking 50ul of supernatant, and performing ELISA detection; the positive well broth was transferred to about 1ml of HT medium and cultured in 24-well plates and assayed 2-3 days later
Example 3
This example opens and verifies the antibody binding method. In order to detect the affinity of the antibody AXL-his and the antibody Anti-AXL-10G5(hIgG1/mIgG2a), the ELISA experimental steps are optimized as follows:
1.1 AXL-his (0.7322mg/ml LOT: 20191112 frozen at-80 ℃) (96-well Fbottom plate manufacturer: Constar); coating concentration: 0.5 mu g/mL; 1 mu g/mL; 2 mu g/mL; 5 μ g/mL, 50 μ L/well, 16 wells each (PBS dilution), incubation: at 37 ℃ for 2 h; washing: PBST plate washing 3 times;
1.25% skimmed milk powder, 200 μ L/well, sealed overnight at 4 deg.C; washing: PBST plate washing 3 times;
1.3 immersing the polished electrode in ethanol for 5s of short-time ultrasonic treatment, then immersing the electrode in deionized water, cleaning the electrode with the deionized water for 5s of short-time ultrasonic treatment, and airing the electrode in air for later use;
1.4 Primary antibody: Anti-AXL-10G5(hIgG1/mIgG2a) is diluted in a gradient way, the sample is added, the reaction is carried out for 1h at 37 ℃, and a chessboard titration method is adopted;
TABLE 1 chessboard titration method
The plates were washed 5 times with PBST at 50. mu.L/well, 37 ℃ for 1h
1.5 Goat-Anti-mouse Fc-HRP 1:50000, 50 μ L/well, 37 deg.C, 1 h; wash plate 5 times with PBST solution
Goat-Anti-human Fc-HRP 1:50000, 50 μ L/well, 37 deg.C, 1 h; washing: PBST washing plate 5 times;
1.6 TMB substrate color development solution (manufacturer: Sigma, cat # T4444), 50 muL/hole, developing for 2-10 min at 37 ℃ or room temperature;
1.7 with 2M H2SO4At 50. mu.L/wellDosing into 96-well plates; reading an OD value by an enzyme-labeling instrument at 450 nm; and carrying out experimental results and data analysis.
The result analysis of the actual data is shown in fig. 1, and it can be seen that the experimental method obtained by the experiment is stable and reliable.
Example 4
In this example, the optimization of ELISA assay for detecting the blocking effect of Anti-AXL-mIgG2a on the binding of receptor AXL-mFc and ligand Gas6-his is as follows:
1.1 Using the antigen Gas6-his (LOT: 20191015 at 1mg/mL frozen at-20 ℃) (96-well Fbottom plate manufacturer: Constar) at a coating concentration of 4. mu.g/mL and adding the solution to each well at 50. mu.L/well for 8 wells (and diluting with PBS solution); and (3) incubation: at 37 ℃ for 2 h; washing: PBST plate washing 3 times;
1.25% of skimmed milk powder, 200 mu L/hole, sealing at 37 ℃ for 2 h; washing: PBST plate washing 3 times;
1.3 AXL-mFc (0.5 mu g/ml) and Anti-AXL-mIgG2a are diluted in a gradient way for 1:1 mixing and preincubation at 37 ℃ for 60min, sample adding and reaction at 37 ℃ for 1 h; PBST washing plate 5 times at 37 deg.C and 1h in 50 μ L/well;
table 2 method of dilution titration is as follows:
1.4 washes with Goat-Anti-mouse Fc-HRP 1:50000, 50. mu.L/well, 37 ℃, 1 h: PBST washing plate 5 times; developing color of TMB substrate (manufacturer: Sigma, goods number: T4444) at 50 μ L/hole at 37 deg.C or room temperature for 2-10 min; the reaction was stopped with 2M H2SO4, 50. mu.L/well; and reading OD value by a microplate reader at 450nm and analyzing the experimental result and data.
The experimental results are shown in table 3 and fig. 2; the results of the experiment were analyzed using Graphpad Prism software.
It can be seen that the inhibition rate of the antibody becomes higher as the concentration increases.
TABLE 3 inhibition experiments
Example 5
In this example, the method of screening cells by flow cytometry was investigated and improved to detect the affinity of HeLa cells to the antibody Anti-AXL-10G5(mIgG2a), and the detection method included:
1.1 Hela cells were digested with pancreatin, counted, and the cell density was adjusted to 3X 106Per mL transfer 100. mu.L of cell suspension to a round bottom 96-well plate (manufacturer: Constar) for a total of 17 wells; placing on an ice box for later use;
1.2 centrifuge at 1000rpm for 2min, Buffer resuspend wash once, centrifuge off supernatant (ice box operation) Buffer: DMEM + 1% BSA;
1.3 Anti-AXL-10G5(mIgG2a) (1.9303mg/mL) antibody gradient dilution, 8-point calibration of the curve, and setting multiple holes at the same time, and performing incubation on an ice box; adding 50 μ L of the suspension into the cell precipitate, re-suspending the cells, mixing, and incubating on ice for 30 min; centrifuging at 1000rpm for 2min, performing once buffer heavy suspension washing, centrifuging to remove supernatant, and centrifuging to obtain 100 μ L; buffer resuspension (on ice box operation);
table 4 methods of antibody dilution are as follows:
1.4 adding 50 mu L of the mixture into the cell suspension by a PE-Goat-Anti-mouse IgG1:300 suction method, incubating the mixture on ice for 30min, centrifuging to remove the supernatant, performing buffer resuspension washing once, centrifuging to remove the supernatant, and performing buffer resuspension of about 200 mu L (ice box operation);
1.5 transfer the cell suspension to a 1.5mL EP tube; detecting a PE fluorescence signal value by adopting a flow cytometer; and carrying out experimental results and data analysis.
The experimental results are shown in fig. 3, and it can be seen that the screening method obtained by the present embodiment is more effective.
Example 6
In this example, hybridoma cells were selected, and the method for selecting hybridoma cells includes the following steps:
1.1 AXL-his antigen was diluted with coating solution, and 2. mu.g of antigen was coated in each well; adding 50 mu L/hole into the hole of an enzyme label plate, and coating for 2 hours at 4 ℃ overnight or 37 ℃; discarding the liquid in the hole, washing with washing solution for 3 times, patting to dry, adding 200 μ L of sealing solution into each hole, sealing at 4 deg.C overnight or 37 deg.C for 2 hr;
1.2 washing with a washing solution for 3 times; at this time, the coating plate can be stored at-20 ℃ or 4 ℃ for later use; adding 50 mu L of hybridoma cell culture supernatant to be detected in each hole, and simultaneously setting positive and negative control holes; incubation at 37 ℃ for 1 hour; washing and drying;
1.3 adding enzyme-labeled secondary antibody, incubating at 37 ℃ for 1 hour with 50 mu L of each well, washing, and patting dry; adding 50 μ L of substrate solution TMB, and developing at 37 deg.C for 2-15 min; at 1mol/L H2SO4Stopping the reaction, and reading an OD value by an enzyme-labeling instrument at 450 nm;
1.4 judging the result: the result shows that 80 hybridoma cell high positive antibody strains are obtained by screening, and the 450nm positive OD values are all more than 1.
Second round of screening was performed
2.1 Gas6-his (LOT: 20191015 at 1mg/mL frozen at-20 ℃ C.) (96-well F bottomplate manufacturer: Constar); coating concentration: 2 μ g/mL, 50 μ L/well, 8 wells (PBS dilution): at 37 ℃ for 2 h; washing: PBST plate washing 3 times;
2.2 sealing with 5% skimmed milk powder at 200 μ L/well at 37 deg.C for 2 h; washing the plate with PBST solution for 3 times;
2.3 mixing AXL-mFc (0.5 mu g/mL) with hybridoma cell supernatant at a ratio of 1:1, simultaneously setting up positive and negative control holes, pre-incubating at 37 ℃ for 30min, transferring the plate, 50 mu L/hole, 37 ℃, 1h, and washing the plate with PBST for 5 times;
2.4 using Goat-Anti-mouse Fc-HRP 1:50000, 50 μ L/hole, 37 deg.C, 1 h; washing the plate with PBST solution for 5 times;
2.5 developing with TMB substrate developing solution (manufacturer: Sigma, cat # T4444) at 50 μ l/well at 37 deg.C or room temperature for 2-15 min; 2M of H2SO4,50μ L/well; reading an OD value by an enzyme-labeling instrument at 450 nm; and analyzing the experimental results and data.
According to the experimental results, two hybridoma cell strains with higher diagnosis efficiency are obtained by screening, and the blocking efficiency is respectively as follows: 41.93% and 40.08%.
The embodiments described above are some, but not all embodiments of the present application. The detailed description of the embodiments of the present application is not intended to limit the scope of the claimed application, but is merely representative of selected embodiments of the application. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present application.
Claims (10)
1. A method for preparing and screening hybridoma cells that secrete an AXL antibody, comprising the steps of:
injecting 50 mu g of AXL immunogen mixture into an immunized mouse, and detecting the antibody titer, wherein the antibody titer reaches 106Stopping immunization;
taking a spleen of a mouse, and preparing splenocyte fluid; adding a PEG solution into the spleen cell fluid and the myeloma cell fluid under the condition of water bath at 40 ℃ for fusion, and centrifuging to obtain a hybridoma cell mixture;
resuspending the hybridoma cell mixture;
coating an AXL antigen, adding the hybridoma cell mixture, incubating for 1h, washing and patting to be dry, adding a secondary antibody, incubating and patting to be dry, and terminating reaction and screening to obtain a positive hybridoma cell secreting an AXL antibody; and detecting the affinity of the hybridoma cells by ELISA.
2. The method for preparing and screening hybridoma cells secreting AXL antibody according to claim 1, wherein the AXL immunogen mixture is obtained by mixing AXL-mFc fusion protein and freund's complete adjuvant in a mass ratio of 1: 1;
the method also comprises 3 times of boosting immunity before the detection of the antibody titer; the immunogen for strengthening immunity is obtained by mixing AXL-mFc fusion protein and Freund's incomplete adjuvant according to the mass ratio of 1: 1; the booster immunization was performed once every two weeks.
3. The method for screening hybridoma secreting AXL antibody according to claim 1, wherein said myeloma cells are SP20 cells, and the concentration of SP20 cells is 1 x 107one/mL.
4. The method of claim 1, wherein the ratio of said spleen cells to said myeloma cells is 3: 1.
5. The method of claim 1, wherein the PEG solution is pre-heated to 40 ℃.
6. The screening method of claim 5, wherein resuspending the hybridoma cell mixture comprises diluting the cells to 5 x 10 with 20% FBS medium4Concentration per well, 5% CO at 37 ℃2Culturing for 7-10 days under the condition.
7. The method for screening hybridoma cells secreting AXL antibody according to claim 1, wherein the amount of AXL antigen coated is 2 μ g/well.
8. The method of claim 7, wherein the conditions for screening positive secreted AXL antibody are OD450The value is greater than 1.
9. The method for screening hybridoma secreting AXL antibody according to claim 1, wherein said antigen for detecting the affinity of said hybridoma is Gas 6-His.
10. The method for screening hybridoma secreting AXL antibody according to claim 9, wherein 0.5 μ g/mL AXL-mFc is mixed with said hybridoma at a ratio of 1:1 as primary antibody.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911371276.XA CN110982791A (en) | 2019-12-26 | 2019-12-26 | Preparation and screening method of hybridoma cells secreting AXL antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911371276.XA CN110982791A (en) | 2019-12-26 | 2019-12-26 | Preparation and screening method of hybridoma cells secreting AXL antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110982791A true CN110982791A (en) | 2020-04-10 |
Family
ID=70077626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911371276.XA Pending CN110982791A (en) | 2019-12-26 | 2019-12-26 | Preparation and screening method of hybridoma cells secreting AXL antibody |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110982791A (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101918452A (en) * | 2007-11-15 | 2010-12-15 | 中外制药株式会社 | Monoclonal antibody capable of binding to Anexelekto, and use thereof |
CN102421802A (en) * | 2009-05-11 | 2012-04-18 | U3制药有限公司 | Humanized axl antibodies |
CN103154020A (en) * | 2010-01-22 | 2013-06-12 | 小利兰·斯坦福大学托管委员会 | Inhibition of axl signaling in anti-metastatic therapy |
CN103747803A (en) * | 2011-06-22 | 2014-04-23 | 国家医疗保健研究所 | Anti-AXL antibodies and uses thereof |
CN103998468A (en) * | 2011-11-03 | 2014-08-20 | 皮埃尔法布雷医药公司 | Antigen binding protein and its use as addressing product for the treatment cancer |
CN110483639A (en) * | 2018-05-15 | 2019-11-22 | 复旦大学 | Target antibody and the antibody-drug conjugates and its preparation method and application of AXL |
CN110540592A (en) * | 2018-05-29 | 2019-12-06 | 杭州尚健生物技术有限公司 | Antibodies that bind to AXL protein and uses thereof |
-
2019
- 2019-12-26 CN CN201911371276.XA patent/CN110982791A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101918452A (en) * | 2007-11-15 | 2010-12-15 | 中外制药株式会社 | Monoclonal antibody capable of binding to Anexelekto, and use thereof |
CN102421802A (en) * | 2009-05-11 | 2012-04-18 | U3制药有限公司 | Humanized axl antibodies |
CN103154020A (en) * | 2010-01-22 | 2013-06-12 | 小利兰·斯坦福大学托管委员会 | Inhibition of axl signaling in anti-metastatic therapy |
CN103747803A (en) * | 2011-06-22 | 2014-04-23 | 国家医疗保健研究所 | Anti-AXL antibodies and uses thereof |
CN103998468A (en) * | 2011-11-03 | 2014-08-20 | 皮埃尔法布雷医药公司 | Antigen binding protein and its use as addressing product for the treatment cancer |
CN110483639A (en) * | 2018-05-15 | 2019-11-22 | 复旦大学 | Target antibody and the antibody-drug conjugates and its preparation method and application of AXL |
CN110540592A (en) * | 2018-05-29 | 2019-12-06 | 杭州尚健生物技术有限公司 | Antibodies that bind to AXL protein and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105209489B (en) | For the specific detection tool for the circulating tumor cell that interstitial and epithelial-mesenchymal convert | |
Crisera et al. | Expression and role of laminin-1 in mouse pancreatic organogenesis. | |
CN107022029B (en) | Monoclonal antibody for detecting alpha-fetoprotein with high specificity and high sensitivity, kit and application | |
CN103243074B (en) | Human colorectal adenocarcinoma tumor cell line as well as preparation method and application thereof | |
CN105779386B (en) | A kind of application of mescenchymal stem cell in preparation treatment M5 type leukemia medicament | |
CN105950561A (en) | Products and preparation method of double chimeric antigen receptor gene modified T lymphocyte targeting breast cancer stem cells | |
UA120264C2 (en) | Therapeutic methods and compositions | |
CN108265027A (en) | Tumor specific T cells and its construction method based on non-natural glycometabolism engineering | |
CN102430118B (en) | Application of H22 liver cancer cell autophagosome to preparation of liver cancer therapeutic vaccine | |
Chen et al. | Mechanical strain promotes proliferation of adipose-derived stem cells through the integrin β1-mediated rhoA/myosin light chain pathway | |
CN114957484A (en) | CAR vector targeting solid tumor cell B7-H3 protein, CAR-T cell and construction method and application thereof | |
CN117050183B (en) | Blocking antibody of PTN-PTPRZ1 pathway and application of blocking antibody in glioma targeted therapy | |
CN104164407B (en) | Anti(pig erythrocyte CR1-like) monoclonal antibody and preparation thereof | |
CN103923212A (en) | EHD2 antibody and application of EHD2 antibody to preparation of immunohistochemical detection reagent for breast cancer | |
CN116462758B (en) | Anti-human PTPRZ1 monoclonal antibody and application thereof in cell flow | |
CN115947835B (en) | Antibody targeting influenza B virus nucleoprotein and application thereof | |
CN104965083B (en) | A kind of kit of detection H3N2 hypotype canine influenza virus | |
CN110982791A (en) | Preparation and screening method of hybridoma cells secreting AXL antibody | |
CN110129272A (en) | Stablize the PK-15 cell strain for expressing MAP3K8 albumen and its building and application | |
CN107325167B (en) | Affinity peptide P296 targeting AKAP3 | |
CN105403710A (en) | Application of EHD2 antibody in preparation of lung cancer immunohistochemical detection reagent | |
CN107460170A (en) | The foundation and its application of Pituitary adenoma cell system | |
CN112553156A (en) | Method for effectively improving production of mesenchymal stem cell cytokines | |
CN112274534A (en) | Application of ATPIF1 gene-knocked-down dendritic cells in tumor prevention and treatment | |
CN104945496A (en) | Polypeptide and application thereof in preparing and purifying EHD2-specific antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200410 |